BRAF and melanoma: Often, class III BRAF mutants in tumors co-exist with RAS mutations or neurofibromin 1 (NF1) deletions (melanomas) or RTK upregulation (lung and colorectal cancers), highlighting the need for concurrent mechanisms for sustaining RAS activation despite ERK-dependent feedback [34].